GnRH

Gonadotropin-Releasing Hormone (GnRH) is a 10-amino-acid peptide synthesised by hypothalamic neurons in the medial preoptic area and arcuate nucleus. It is released into hypophyseal portal circulation in pulsatile bursts at approximately 90-minute intervals during the adult male reproductive state. The pulse frequency, rather than amplitude, encodes the signal that downstream pituitary gonadotrophs translate into LH and FSH secretion.

The pulsatility principle:

Knobil 1980, Recent Prog Horm Res established the foundational principle: continuous GnRH exposure desensitises the pituitary GnRH receptor (GnRHR) within hours, producing paradoxical suppression of LH and FSH despite high ligand availability. Pulsatile delivery maintains receptor responsiveness; continuous delivery shuts the system down. This is why GnRH agonists (leuprolide, goserelin) used in prostate cancer therapy produce chemical castration through continuous receptor occupation rather than physiological signal mimicry.

The pulse-frequency code distinguishes male from female reproductive physiology. Adult males show ~90-minute pulses producing balanced LH and FSH secretion. Adult females show frequency variation across the menstrual cycle — slower pulses favour FSH (follicular development), faster pulses favour LH (ovulation trigger).

The HPTA cascade:

GnRH binds GnRHR on pituitary gonadotroph cells, activating G-protein-coupled signalling that triggers LH and FSH synthesis and release. LH stimulates testicular Leydig cells to synthesise testosterone from cholesterol via the steroidogenic pathway. FSH stimulates Sertoli cells to support spermatogenesis. Circulating testosterone and its estradiol metabolite feed back negatively at both hypothalamic GnRH neurons and pituitary gonadotrophs, completing the loop.

Exogenous androgen suppression mechanism:

Exogenous testosterone administration produces sustained supraphysiological serum testosterone. The hypothalamus registers chronic saturation; GnRH pulse frequency drops; pituitary LH and FSH secretion falls below detection within 14 days on standard testosterone protocols. Without LH drive, Leydig cells atrophy. Without FSH, spermatogenesis halts.

Recovery requires GnRH pulsing to resume — which requires removal of the negative-feedback signal (via testosterone clearance) plus removal of any residual feedback brake (via SERM intervention if needed). The kinetics of GnRH pulse-pattern restoration are not always synchronous with serum LH measurement; Veldhuis et al. 2013, J Clin Endocrinol Metab reviewed the pulse-pattern recovery as the operative central signal that single-point LH measurement underrepresents.

Clinical relevance:

The pulsatility principle explains why post-cycle SERM intervention (tamoxifen, clomiphene) works. SERMs occupy hypothalamic estrogen receptors without agonist activity, removing the feedback brake on GnRH neurons and allowing physiological pulse frequency to resume. The intervention restores the central signal without bypassing the pituitary or directly stimulating the testes — that distinction matters when comparing SERM-based PCT to hCG (which bypasses the hypothalamus entirely by acting as an LH analogue at Leydig cells).

Kisspeptin, a more recently characterised hypothalamic peptide, regulates GnRH neuron firing upstream and may emerge as a future therapeutic target for HPTA recovery. As of current clinical practice, SERM and hCG remain the available pharmacological tools.